First Patient Dosed in the Phase I/II Study of Umecrine Mood’s Candidate Drug for Premenstrual Dysphoric Disorder
5/23/2013 10:00:39 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
STOCKHOLM – May 23, 2013. Umecrine Mood AB announced today that dosing has been
initiated in a randomized Phase I/II study of UC1010 for the treatment of
patients with premenstrual dysphoric disorder (PMDD). Umecrine Mood is part of
the Karolinska Development portfolio.
Help employers find you! Check out all the jobs and post your resume.
comments powered by